Paper Review Records
All Paper Review Records
29 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
158
days
Disparities in Treatment Patterns for Advanced ALK ‐ and EGFR ‐Mutated Non‐Small Cell Lung Cancer Patients in Mexico
Authors
Luis Arturo Sanchez Trujillo; Diego Armando Díaz García; Ida Caterina García‐Appendini; Nohemi Caballero; Nils Ramirez Knape; Sandra Evangelina Herrera; Jose Francisco Olguin; Guilherme Silva JulianShow moreShow less
Affiliations
1. Pfizer México Mexico City Mexico; 2. Oncology Department Hospital Ángeles Del Carmen Guadalajara Jalisco Mexico; 3. Real World Insights (RWI), IQVIA Ciudad de Mexico Mexico; 4. Real World Insights (RWI), IQVIA Bogotá Colombia; 5. Evidence Generation Emerging Markets Pfizer São Paulo BrazilShow moreShow less
150
days
Transesophageal Endoscopic Ultrasound With Bronchoscope‐Guided Fine‐Needle Aspiration for Tissue Diagnosis of Pleural Malignancy in a Patient With Respiratory Compromise
Authors
So‐Yun Kim; Chaeuk Chung; Dongil ParkShow moreShow less
Affiliations
1. Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine Chungnam National University Hospital Daejeon Republic of Korea; 2. Department of Internal Medicine College of Medicine, Chungnam National University Daejeon Republic of KoreaShow moreShow less
137
days
Prognostic Value of Early Dynamic Changes in Skeletal Muscle Index for Unresectable Lung Squamous Cell Carcinoma: A Prospective Landmark Analysis
Authors
Xinjie Zhang; Xueni Liu; Chenglan Ye; Yixiao Fu; Jie Chen; Minhua Wu; Jianhui Huang; Yanru XieShow moreShow less
Affiliations
1. Department of Cancer Center The Fifth Affiliated Hospital of Wenzhou Medical University (Lishui Central Hospital) Lishui ChinaShow moreShow less
51
days
Protocol of a Real‐World Prospective Observational Study of Amivantamab Plus Chemotherapy in Patients With EGFR Exon 20 Insertion–Positive Non‐Small Cell Lung Cancer ( SPIRAL ‐ RACER20 Study)
Authors
Ryo Sawada; Tadaaki Yamada; Takayuki Shimose; Masaki Ishida; Hayato Kawachi; Naoya Nishioka; Masahiro Iwasaku; Shinsaku Tokuda; Tohru Inaba; Koichi TakayamaShow moreShow less
Affiliations
1. Department of Pulmonary Medicine, Graduate School of Medical Science Kyoto Prefectural University of Medicine Kyoto Japan; 2. Department of Statistics and Data Center Clinical Research Support Center Kyushu Fukuoka Japan; 3. Kyoto Prefectural Institute of Public Health and Environment Kyoto Japan; 4. Department of Infection Control and Laboratory Medicine Kyoto Prefectural University of Medicine Kyoto JapanShow moreShow less
260
days
Transformation to Small‐Cell Lung Carcinoma and Then to Sarcomatoid Carcinoma in an EGFR ‐Mutant Lung Adenocarcinoma Patient During Systemic Therapy: A Case Report
Authors
Bingyu Huang; Tao Lu; Ruping Hong; Xiaoyan Liu; Xiaoxing Gao; Yan Xu; Minjiang Chen; Wei Zhong; Mengzhao Wang; Jing ZhaoShow moreShow less
Affiliations
1. Department of Internal Medicine Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Beijing China; 2. Department of Pathology Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Beijing China; 3. Department of Pulmonary and Critical Care Medicine Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Beijing ChinaShow moreShow less
111
days
Exhaled Breath Analysis for Lung Cancer Detection: From VOCs Signatures to EBC ‐Based Liquid Biopsy and Clinical Translation
Authors
Penghai Sun; Zhenkai Fu; Shaodong Wang; Yun Li; Mantang QiuShow moreShow less
Affiliations
1. Department of Thoracic Surgery Peking University People's Hospital Beijing China; 2. Thoracic Oncology Institute Peking University People's Hospital Beijing China; 3. Research Unit of Intelligence Diagnosis and Treatment in Early Non‐Small Cell Lung Cancer Chinese Academy of Medical Sciences, 2021RU002 Beijing China; 4. Institute of Advanced Clinical Medicine Peking University Beijing China; 5. Frontiers Science Center for Cancer Integrative Omics Peking University People's Hospital Beijing ChinaShow moreShow less
FAQ
How long does Thoracic Cancer take to review a manuscript?
As of 2026-11-18, CrushSCI has 29 complete review records for Thoracic Cancer. The fastest paper went from submission to acceptance in 30 days (Delayed Occurrence of Lung Cancer Leptomeningeal Metastasis and Era‐Associated Post‐ LM Survival: A 14‐Year Single‐Center Cohort Study, received 2026-07-19, accepted 2026-08-18); the slowest took 327 days. The average is 124 days and the median is 122 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
